Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases

Molecular Cancer Therapeutics

Volumn 5, Issue 7, 2006, Pages 1883-1894

  Troiani, Teresa ^a   Lockerbie, Owen ^a   Morrow, Mark ^a   Ciardiello, Fortunato ^b   Eckhardt, S Gail ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PROTEIN RET; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; G2 PHASE; HUMANS; ORGANOPLATINUM COMPOUNDS; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 33748310873     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0055     Document Type: Article

References (54)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. Cancer J Clin 2005;1:10-30.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
3. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;16:2938-47.
4. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) versus weekly high dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002;21:129.
5. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998;37:285-9.
6. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21: 105-15.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
8. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-46.
9. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-60.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;4:337-45.
11. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1, and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000;2:174-81.
12. Ellis LM, Liu W. Vascular endothelial growth factor (VEGF) expression and alternate splicing in non-metastatic and metastatic human colon cancer cell lines. Proc Am Assoc Cancer Res 1995;36:88.
13. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999;6:845-50.
14. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;6:748-53.
15. Shiraishi A, Ishihwata T, Shoji T, Asano G. Expression of PCNA, basic fibroblast growth factor, FGF-receptor, and vascular endothelial growth factor in adenomas and carcinomas of human colon. Acta Histochem Cytochem 1995;28:21-9.
16. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;18:3964-8.
17. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;5: 1011-27.
18. Amaya H, Tanigawa N, Lu C, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival, and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997;119:227-35.
19. Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998;77: 998-1002.
20. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379-84.
21. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000;6:2803-7.
22. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53.
23. Takahashi Y, Tucker SL, Kitadai Y. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997;5:541-6.
24. Rosen LS. Inhibitors of the vascular endothelial growth factor receptor. Hematol Oncol Clin North Am 2002;5:1173-87.
25. Presta LG, Chen H, O'Connor SJ. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
26. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
27. Wedge SR, Ogilvie DJ, Dukes M. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum anti-tumor efficacy. Cancer Res 2000;60:970-5.
28. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
29. Brekken RA, Overholser JP, Stastny VA, Waltenberg J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
30. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-8.
31. Inoue K, Slaton JW, Davis D, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the antivascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000;6:2635-43.
32. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anticancer therapy, by anti-VEGF neutralizing monoclonal antibodies and VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999;18:473-81.
33. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000;79:1-38.
34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;23:2335-42.
35. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
36. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
37. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.
38. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1931-9.
39. Heymach JV, Johnson BE, Rowbottom JA, et al. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Proc Am Soc Clin Oncol 2005;24:3023.
40. Johnson B, Ma P, West H, et al. Preliminary phase II safety evaluation of ZD6474 in combination with carboplatin and paclitaxel, as first line treatment in patients with NSCLC. Proc Am Soc Clin Oncol 2005;74:7102.
41. Xu JM, Azzariti A, Colucci G. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 2003;6:442-8.
42. Chen CR, Wang W, Rogoff HA, Xiaotong Li, Mang W, Chiang Li. Dual induction of apoptosis and senescence in cancer cells by ChK2 activation: checkpoint activation as a strategy against cancer. Cancer Res 2005;14: 6017-21.
43. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;22:7764-74.
44. Rice PL, Beard KS, Driggers LJ, Ahnen DJ. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res 2004; 22:8148-51.
45. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002;10:3259-69.
46. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
47. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84.
48. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - a phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:7011.
49. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;16:2647-53.
50. Rydén L, Linderholm B, Nielsen NH, Emdin S, Johnson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003;3:147-54.
51. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004;1:11-9.
52. Azzariti A, Xu JM, Porcelli L, Paradiso A. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004; 1:135-44.
53. Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:61-8.
54. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 2002;57:8723-31.